Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;47(6):101017.
doi: 10.1016/j.currproblcancer.2023.101017. Epub 2023 Sep 27.

Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Muhammet Ali Kaplan  1 , Mehmet Ali Nahit Şendur  2 , Ayten Kayı Cangır  3 , Pınar Fırat  4 , Erdem Göker  5 , Saadettin Kılıçkap  6 , Başak Oyan  7 , Ayşim Büge Öz  8 , Feyyaz Özdemir  9 , Gökhan Özyiğit  10
Affiliations
Free article
Review

Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Muhammet Ali Kaplan et al. Curr Probl Cancer. 2023 Dec.
Free article

Abstract

Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.

Keywords: Biomarker; Cancer; Chemotherapy; Immune checkpoint inhibitor; Immunotherapy; Pleural mesothelioma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Kaplan is on Advisory Boards of Roche, Bristol Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Bayer, Pfizer, and Abdi Ibrahim Ilac and reports honoraria from Roche, BMS, MSD, Bayer, Pfizer, Amgen, Astra Zeneca, Nobel, and Astellas; all outside the submitted work. Dr. Şendur is on Speaker's Bureau for BMS, MSD, Pfizer, Amgen, Novartis, and Astellas and is on Advisory Boards of Amgen, BMS, MSD, Pfizer, Roche, Novartis, Astellas, and Takeda; all outside the submitted work. Dr. Kayı Cangır has declared no conflict of interest. Dr. Fırat has declared no conflict of interest. Dr. Göker is on Speaker's Bureau for BMS, MSD, Amgen, Pfizer, Novartis, Astra Zeneca, Roche, Jansen Cilag, Takeda, Astellas, and Lilly and is on Advisory Boards of Amgen, BMS, MSD, Pfizer, Novartis, Astra Zeneca, and Roche; all outside the submitted work. Dr. Kılıçkap has declared no conflict of interest. Dr. Oyan reports research support for clinical trials through institution from Novartis and honoraria from BMS, Amgen, Novartis, Pfizer, Astra Zeneca, Roche, and MSD, and is on Advisory Boards of Takeda, Roche, Astra Zeneca, MSD, Novartis, Amgen, and Gilead; all outside the submitted work. Dr. Öz has declared no conflict of interest. Dr. Özdemir has declared no conflict of interest. Dr. Özyiğit has declared no conflict of interest.

Publication types

LinkOut - more resources